249 articles in this topic
Breakthrough combination therapy shows dramatic survival improvements over standard treatment in late-stage colorectal cancer patients.
Zanidatamab achieved 44% response rate in small study of patients with aggressive salivary gland tumors, offering new hope for rare cancer.
New combination therapy achieved 32% response rate in hard-to-treat endometrial cancer patients with specific genetic markers.
Innovative treatment combining three powerful drugs achieved 85% progression-free survival at one year in high-risk patients.
Phase I trial shows NT-I7 safely increases lymphocyte counts and expands cancer-fighting T cells in high-grade glioma patients.
Researchers find new therapeutic potential in existing medication for treating challenging desmoid tumors.
Tislelizumab plus anlotinib achieved promising results in treating advanced pulmonary sarcomatoid carcinoma with manageable side effects.
Combining CSF1R inhibitor with chemotherapy enhanced immune response and improved outcomes in triple-negative breast cancer patients.
Breakthrough combination therapy challenges current standard treatment for PD-L1-positive lung cancer patients.
New AI model analyzes standard pathology slides to predict cancer recurrence risk, potentially replacing expensive genetic tests.
Bireociclib plus fulvestrant significantly improved outcomes in advanced hormone-positive breast cancer patients.
A pediatric oncologist reflects on living with multiple cancers throughout his career and life.
